Most cited papers from Avail Clinical Research

Avail Clinical Research

What are the most cited papers from Avail Clinical Research?

The most cited paper from Avail Clinical Research is "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C" (Eric Lawitz, Daniel Gruener, John M. Hill et al., 2012), with 158 citations. Next come "GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study" (65) and "Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C" (31).

Published FieldAccess

Showing 19 of 19 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C Eric Lawitz, Daniel Gruener, John M. Hill et al. · Journal of Hepatology	5 Feb 2012	158
2	GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study Maribel Rodriguez‐Torres, S. Glass, John M. Hill et al. · Journal of Viral Hepatitis Open access	9 Mar 2016	65
3	Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C Eric Lawitz, Daniel Gruener, Thomas C Marbury et al. · Antiviral Therapy	8 Aug 2014	31
4	High levels of functional divergence in toxicity towards prey among the venoms of individual pigmy rattlesnakes Sarah A. Smiley-Walters, Terence M. Farrell, H. Lisle Gibbs · Biology Letters Open access	6 Feb 2019	25
5	A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4 Bradley D. Vince, John M. Hill, Eric Lawitz et al. · Journal of Hepatology Open access	14 Jan 2014	24
6	A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol James H. Pickar, Julia M. Amadio, John M. Hill et al. · Menopause The Journal of The North American Menopause Society Open access	2 Feb 2016	18
7	Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson’s Disease. (P2.8-047) Andrew M. Goldfine, Robert D. Faulkner, S. Vasu et al. · Neurology	9 Apr 2019	11
8	A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients Eric Lawitz, John M. Hill, Thomas C Marbury et al. · Antiviral Therapy	9 Oct 2012	11
9	1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885 Eric Lawitz et al. · Journal of Hepatology	Mar 2011	11
10	876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS Andrew Joseph Muir, John M. Hill, Erik Lawitz et al. · Journal of Hepatology	Apr 2013	10
11	1218 HIGH SUSTAINED VIROLOGICAL RESPONSE (SVR) RATE AFTER DANOPREVIR FOR ONLY 14 DAYS ASSOCIATED WITH PEG-INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS P. Larrey, Christophe Carenco, Dominique Guyader et al. · Journal of Hepatology Open access	Mar 2011	8
12	847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS Eric Lawitz, John M. Hill, Bradley D. Vince et al. · Journal of Hepatology Open access	Apr 2013	5
13	1204 THE PEPSI PROJECT: HCV RESISTANCE SCREENING AND PREDICTION OF PI-CONTAINING THERAPY OUTCOME A.M. Sirkoski, Saleta Sierra, N. Qurishi et al. · Journal of Hepatology	Apr 2013	2
14	https://journals.flvc.org/fjer/article/view/134002 Barbara Lockhart · Florida Educational Research Association	11 Nov 1965	0
15	Letters none · Journal of Forestry Open access	Aug 1977	0
16	846 CHARACTERIZATION OF THE EARLY VIRAL KINETICS IN COMPENSATED CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS TREATED WITH BOCEPREVIR AND TELAPREVIR Cédric Laouenan, Jérémie Guedj, Martine Lapalus et al. · Journal of Hepatology	Apr 2013	0
17	1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C Eric Lawitz, Daniel Gruener, T.C. Marbury et al. · Journal of Hepatology Open access	Apr 2013	0
18	375 EFFICACY AND SAFETY OF TWICE-DAILY DOSING OF CONTROLLED-RELEASE HYDROCODONE AND ACETAMINOPHEN TABLETS FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-COONTROLLED STUDY Larry Gilderman, J. Box, Bruce M. Rankin et al. · Osteoarthritis and Cartilage Open access	Dec 2007	0
19	Does an Electronic Infant Security System Ensure a More Secure Hospital Environment?: Writing for the Con Position Karen L. Ianacone · MCN The American Journal of Maternal/Child Nursing	24 Aug 2004	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.